Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Author: kodiac

Cyproheptadine

Plain-language summaryIntrigue 56 / 100

Cyproheptadine, sold as Periactin, is a first-generation antihistamine that also potently blocks 5-HT2A and 5-HT2C serotonin receptors. The combination gives it three fairly distinct clinical roles: appetite stimulation (5-HT2C blockade) used in pediatric failure-to-thrive and in cachexia; treatment of serotonin syndrome (5-HT2A blockade rapidly reverses the toxidrome); and migraine prophylaxis. The H1 and anticholinergic activity produces sedation and dry mouth as expected for a first-generation antihistamine. The serotonin syndrome reversal use is the most clinically important and is not interchangeable with other antihistamines. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

45/100

Old approved antihistamine with genuine 5-HT2 probe value and sole antidote status in serotonin syndrome

Cyproheptadine has been around since 1961. That fact alone shapes how you evaluate it as a research compound. The mechanism, the clinical uses, the pharmacology — all of it is mapped. There’s no meaningful “is this real” question left to ask.

What keeps it relevant is a narrow but genuinely useful set of properties. The dual H1 and 5-HT2A/5-HT2C antagonism profile isn’t something you replicate cleanly with newer, more selective agents. If you need to study the serotonin syndrome reversal mechanism or the appetite-stimulation pathway driven by 5-HT2C blockade, cyproheptadine is the canonical tool. It’s what investigators reach for when they want the combined H1/5-HT2 blockade signal in a single compound. That’s probe value: real, but narrow.

The serotonin syndrome angle is probably the most clinically interesting thing happening with this compound right now. It remains the only compound with a specific pharmacological rationale as an antidote, and as SSRI/SNRI prescriptions have climbed and combinations with triptans, tramadol, and other serotonergic agents become more common, there’s renewed interest in the reversal mechanism. Honest assessment: most of this is clinical pharmacology, not bench discovery. The compound isnt opening new mechanistic territory. Its confirming what we already know.

The post-SSRI sexual dysfunction research angle is newer and more interesting from a bench perspective. 5-HT2A antagonism is one of the proposed interventions for PSSD, and cyproheptadine gets cited in those discussions. But the evidence there is anecdotal-to-preliminary, and more selective 5-HT2A tools like ketanserin or volinanserin exist for investigators who want clean signal without the H1 confound.

What we think: cyproheptadine earns a place in a research library because of what it is, not what it’s becoming. Its differentiation in the serotonin syndrome space is real. Its evidence quality and translational signal are solid by virtue of six decades of clinical use. But its novelty is essentially zero, and the bench-scale questions it can answer are mostly answered. A serious investigator building a new research program in 2025 would reach for this to confirm a mechanism or use it as a comparator, not as the focus of a program.

We stock it because it’s the reference 5-HT2 antagonist antihistamine with an irreplaceable clinical niche. Thats a legitimate reason. Its just not a reason to call it exciting.

Novelty

20

Mechanism promise

38

In-category differentiation

50

Evidence quality

60

Translational signal

65

Research bench value

50

Rationale Novelty is near-floor for a 1961 approved compound with fully mapped pharmacology, but differentiation and bench value score meaningfully higher because the combined H1/5-HT2A/5-HT2C profile is genuinely unique and its role as the only pharmacological serotonin syndrome antidote is uncontested; strong translational and evidence scores reflect 60-plus years of clinical use, not discovery-stage excitement.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

First-generation antihistamine + 5-HT2 antagonist

A piperidine first-generation antihistamine with 5-HT2A and 5-HT2C antagonist activity; used for appetite stimulation, serotonin syndrome reversal, and migraine prophylaxis.

Abstract

Cyproheptadine (4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine; CAS 129-03-3; molecular formula C21H21N; molecular weight 287.40) is a piperidine first-generation antihistamine with potent 5-HT2A and 5-HT2C antagonist activity, approved by the FDA in 1961 (Periactin). The compound combines H1 antihistamine activity (Ki approximately 1 nM, comparable to diphenhydramine) with strong 5-HT2 antagonism (Ki approximately 1 nM at 5-HT2A); the combined activity drives appetite stimulation (5-HT2C antagonism, the same mechanism as the appetite gain seen with olanzapine and clozapine), serotonin syndrome reversal, and migraine prophylaxis. Plasma half-life is approximately 8 hours. Approved for allergic conditions; off-label use in failure-to-thrive (pediatric appetite stimulation), serotonin syndrome (the only specific antidote besides supportive care), and post-SSRI sexual dysfunction (5-HT2A antagonism). Used as the canonical 5-HT2 antagonist antihistamine in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-353Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Low-Dose Naltrexone (LDN)

Our opinion on this compoundNiche research probe

48/100

Genuinely interesting neuroimmune probe with patchy clinical evidence and an old backbone

Look, the compound itself is ancient. Naltrexone got FDA approval in 1984, and the low-dose angle dates to Bernard Bihari’s clinical observations in the late 1980s. So when we talk about LDN as a research target, we’re not talking about freshness. What we are talking about is a genuinely unusual pharmacological story that most people in the opioid receptor space still dont fully understand.

Here’s the thing that makes LDN interesting: the mechanism isn’t just “antagonize the mu receptor at low dose and call it a day.” The working model involves a brief 4-6 hour blockade that triggers compensatory receptor upregulation and increases in endogenous opioid synthesis — net effect is actually elevated opioid tone over baseline, the opposite of what you’d expect. Layer on top of that the TLR4 antagonism story, where naltrexone’s action on microglial Toll-like receptor 4 attenuates neuroinflammatory signaling through a completely separate pathway. That’s a two-pronged mechanism with real conceptual bite, and the neuroimmune piece is what drives most of the current bench interest.

The problem is the evidence base. We have clinical trials across fibromyalgia, multiple sclerosis, Crohn disease, Hashimoto thyroiditis, and CRPS — but almost all of them are small-N, single-center, and methodologically inconsistent. The Penn fibromyalgia work from Younger’s group is probably the most methodologically serious, and even that produced modest effect sizes. There’s no phase 2/3 replication that would let you say “this is settled.” The translational signal is real in the sense that human subjects clearly respond to something, but “why” remains incompletely characterized and the effect magnitude across populations is not compelling.

What we think is genuinely valuable here is the bench probe application: LDN is a useful tool if you’re studying microglial TLR4 signaling, paradoxical receptor pharmacology, or neuroimmune crosstalk. You can ask questions with it that you can’t ask as cleanly with other compounds in this space. The compounding availability is solid and the base compound’s pharmacokinetics are extremely well-characterized, which means experimental design is tractable. For investigators working at the neuroimmune interface, having LDN in the toolkit makes sense.

What we don’t like: the clinical literature is genuinely messy. Patient advocacy communities have generated most of the pressure to study LDN, which introduces selection bias and publication pressure that makes the human signal harder to parse. If you’re trying to build a rigorous case for any single indication, you’re working against decades of underpowered trials. Interesting compound, credible mechanism, limited evidence base. That combination lands it squarely in the useful-but-not-compelling range for most research programs outside of the neuroimmune niche it was built for.

Novelty

35

Mechanism promise

58

In-category differentiation

52

Evidence quality

42

Translational signal

47

Research bench value

58

Rationale LDN’s dual mechanism — paradoxical opioid tone upregulation plus TLR4/microglial antagonism — is more interesting than a plain receptor story, but naltrexone is a 1984 FDA approval and the LDN angle has been circulating since Bihari’s work; novelty is limited. Evidence across MS, fibromyalgia, and Crohn’s consists of small-N trials with mixed methodology, which floors both evidence quality and translational signal and keeps the overall in the high-40s.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Mu-opioid antagonist (low-dose immunomodulatory use)

A mu-opioid antagonist used at low doses (1.5 to 4.5 mg) for autoimmune and chronic pain conditions; mechanism via transient opioid blockade and TLR4 modulation.

Abstract

Naltrexone ((5alpha)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one; CAS 16590-41-3; molecular formula C20H23NO4; molecular weight 341.40) is a long-acting mu-opioid antagonist approved by the FDA in 1984 (ReVia, Vivitrol) for opioid and alcohol use disorders at standard doses (50 mg/day or 380 mg monthly depot). The low-dose application (LDN, 1.5 to 4.5 mg/day) was developed by Bernard Bihari in the 1980s and has been adopted in immunology and chronic pain communities. Mechanism is multifactorial and incompletely characterized: brief, transient mu-opioid antagonism (only 4 to 6 hours per dose) triggers compensatory upregulation of endogenous opioid synthesis and receptor expression, producing a paradoxical increase in opioid-mediated tone over baseline; secondary TLR4 antagonism on microglia attenuates neuroinflammation. Approved indications: opioid and alcohol use disorders (standard dose). Off-label LDN use in multiple sclerosis, Crohn disease, fibromyalgia, complex regional pain syndrome, and Hashimoto thyroiditis is supported by small clinical trials with mixed methodology. Plasma half-life is approximately 4 hours. Used as a research compound for paradoxical opioid pharmacology and neuroimmune modulation.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-351Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Naloxone

Plain-language summaryIntrigue 64 / 100

Naloxone, sold as Narcan, is the standard reversal agent for opioid overdose. It competitively binds and displaces opioids from the mu-opioid receptor with high affinity, restoring breathing within minutes when administered intramuscularly or as an intranasal spray. Public health programs have made intranasal naloxone available without prescription in pharmacies and from harm-reduction organizations across most of the US, and bystander administration is credited with thousands of overdose reversals annually. The short half-life means re-dosing may be required for long-acting opioids like methadone or fentanyl analogs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

50/100

The canonical opioid antagonist probe; indispensable in its niche but far from a novel research target

Look, naloxone isnt a research target. It’s a research tool. That distinction matters a lot when you’re trying to explain a score of 50, which might seem high for a compound that scores 12 on novelty and 22 on mechanism promise. The thing is, those two axes tell the truth about where naloxone sits right now: it’s a 1971 FDA approval with a completely understood competitive antagonism profile at mu-opioid receptors (Ki approximately 1 nM), and nobody in the field is surprised by any of that. The pharmacology is textbook. The mechanism is single-receptor competitive antagonism, about as mechanistically unexciting as it gets for a research library context.

So why does it score 50 at all? Because evidence quality and translational signal are very real, and bench value is genuinely high. As the canonical short-acting, reversible mu-opioid antagonist, naloxone is what you reach for when you want to attribute an effect to opioid receptor activation. You can’t do serious opioid pharmacology without it. In animal behavioral models, in ex vivo receptor binding, in cell culture signaling studies, naloxone is the probe that closes the loop. There’s a reason every paper on endogenous opioids, opioid-mediated analgesia, or itch involves a naloxone blockade condition. It’s not doing anything exciting on its own; it’s the negative control that makes everything else interpretable.

The evidence base is essentially unimpeachable. FDA approved since 1971. Decades of replicated clinical data on reversal efficacy. The intranasal 4 mg formulation has generated real public health outcome data, and the overdose reversal pharmacokinetics are thoroughly characterized across parenteral and mucosal routes. You’re not going to find an evidence-quality problem here. Translational signal similarly scores high because the clinical effect is binary and unambiguous. That’s about as clean a human signal as this field produces.

What we don’t love is the novelty situation. There’s essentially no fresh angle here for a general-purpose research program. Some investigators are poking at ultra-low-dose naloxone in paradoxical opioid sensitization models, and the toll-like receptor 4 story (the non-stereoselective TLR4 binding that the (+)-naloxone isomer isolates) is genuinely interesting mechanistic territory, but that angle hasnt produced clinical traction and remains a niche debate. The low-dose naltrexone literature is adjacent but uses a different compound with a different half-life and a different evidence trajectory.

We think naloxone belongs in the library as a reference compound: the thing you want well-documented and accessible for any research program that touches opioid receptor modulation. Its score reflects exactly what it is, high value in a specific and narrow research context, low value as a forward-looking research target. The 50 is earned by half the formula, and the other half is where it tells on itself.

Novelty

12

Mechanism promise

22

In-category differentiation

52

Evidence quality

88

Translational signal

85

Research bench value

72

Rationale Naloxone earns its 50 from very high evidence quality and translational signal as a 55-year FDA-approved clinical compound, offset by essentially zero novelty and unremarkable single-receptor mechanism; its library value is as the reference mu-antagonist probe for opioid receptor pharmacology, not as a forward-looking research target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Mu-opioid antagonist (short-acting)

A short-acting mu-opioid antagonist; the standard reversal agent for opioid overdose.

Abstract

Naloxone ((5alpha)-4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one; CAS 465-65-6; molecular formula C19H21NO4; molecular weight 327.37) is a short-acting mu-opioid antagonist approved by the FDA in 1971 (Narcan). The compound is a competitive antagonist at mu, kappa, and delta opioid receptors with preferential mu affinity (Ki approximately 1 nM). Unlike naltrexone, oral bioavailability is poor (less than 5 percent), restricting use to parenteral or intranasal administration. Plasma half-life is approximately 1 to 2 hours, shorter than most opioid agonists, requiring multiple doses or infusion in opioid overdose reversal where the half-life of the offending opioid exceeds naloxone’s. The intranasal formulation (Narcan nasal spray, 4 mg) is widely available and has driven the modern public health response to the opioid overdose epidemic. Approved indications: opioid overdose reversal, postoperative opioid reversal, opioid-induced constipation (IV form alvimopan, methylnaltrexone for that latter). Used as the canonical mu-opioid antagonist in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-352Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Buprenorphine

Plain-language summaryIntrigue 76 / 100

Buprenorphine is a semi-synthetic opioid with an unusual receptor profile that has made it the cornerstone of medication-assisted treatment for opioid use disorder. As a high-affinity partial mu-opioid agonist it activates the receptor enough to suppress withdrawal and craving but with a built-in ceiling on respiratory depression that makes overdose much less likely than with full agonists. Its kappa antagonism may contribute to mood benefit. The combination with naloxone (Suboxone) discourages injection abuse because naloxone is not orally active but blocks opioid effects if injected. Approved for OUD in the US in 2002, it has saved many lives. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundFederally scheduled

57/100

Mature Schedule III MAT agent with a genuinely interesting KOR antagonism angle but limited frontier research appeal

Look, buprenorphine is one of the most clinically important opioid-system compounds ever developed, and that’s precisely why it scores where it does here. The evidence base for OUD treatment is enormous: multiple FDA approvals, decades of real-world data, a well-characterized safety margin built on mu partial agonism. But clinically essential and interesting research target right now are two different questions, and this rubric is asking the second one.

The pharmacology is genuinely interesting. What buprenorphine does is unusual: high-affinity mu binding (Ki approximately 0.2 nM) with roughly 30 percent intrinsic activity, which produces analgesia and craving suppression without the respiratory depression ceiling you get from full agonists. And then layered on top, concurrent kappa-opioid antagonism and ORL1 partial agonism. That’s a legitimately complex pharmacological profile. The KOR antagonism is the angle that keeps serious investigators paying attention. KOR activation is strongly implicated in dysphoria and stress-driven depression, so blocking it while partially activating mu has real mechanistic rationale as an antidepressant approach. Some early clinical data support this, though effect sizes are modest and the literature is still maturing.

Here’s the problem with using buprenorphine as the probe for that question: the mu signal is always in the room. Selective KOR antagonists like aticapant or navacaprant give you cleaner experimental handles on the kappa axis in isolation. With buprenorphine, any behavioral or molecular readout you get in a model is a convolution of at least three receptor activities. Thats not fatal for all research designs, but it limits interpretability in a way that matters for mechanistic work.

From a bench value standpoint, it remains a useful reference tool. If your program involves opioid receptor partial agonism dynamics, tolerance and ceiling-effect modeling, or mu/kappa crosstalk, buprenorphine is the canonical standard. We credit that. The Schedule III status creates meaningful practical friction for investigators who aren’t already operating in a controlled-substance-licensed environment, which is worth acknowledging honestly.

What we don’t see is a strong case for building a new research program around buprenorphine in 2025 unless that program is specifically about OUD pharmacotherapy refinement, KOR biology in mood disorders where selectivity constraints are acceptable, or receptor pharmacology where a mu partial agonist reference is genuinely needed. Important compound, belongs in the library, but isnt where the frontier is.

Novelty

22

Mechanism promise

60

In-category differentiation

58

Evidence quality

78

Translational signal

72

Research bench value

65

Rationale Buprenorphine’s clinical evidence base for OUD is massive but that’s not what drives research scores; novelty is low given a 1981 approval and decades of trodden literature. The kappa-opioid antagonism angle for treatment-resistant depression is the one live research thread, but it’s mechanistically muddied by concurrent mu partial agonism, and cleaner selective KOR antagonists exist as investigational probes. Schedule III cap of 75 does not bind since the calculated score falls below it.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Mu-opioid partial agonist + kappa-opioid antagonist

A semi-synthetic mu-opioid partial agonist with kappa-opioid antagonism; the primary medication-assisted treatment for opioid use disorder.

Abstract

Buprenorphine ((2S,6R,7R,14S)-17-cyclopropylmethyl-7-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6-methoxy-4,5-epoxy-6,14-ethano-morphinan-3-ol; CAS 52485-79-7; molecular formula C29H41NO4; molecular weight 467.65) is a semi-synthetic thebaine-derived mu-opioid partial agonist with concurrent kappa-opioid antagonist and ORL1 (nociceptin receptor) partial agonist activity. Originally approved by the FDA in 1981 as an analgesic; reformulated and approved in 2002 (Subutex, Suboxone) for opioid use disorder. Mu-opioid affinity is high (Ki approximately 0.2 nM) with intrinsic activity approximately 30 percent (partial agonism); the partial agonism produces a ceiling effect on respiratory depression and euphoria, distinguishing buprenorphine safety profile from full agonists like fentanyl or morphine. Long plasma half-life (24 to 60 hours) supports once-daily or less-frequent dosing. Suboxone formulation includes naloxone (a mu antagonist with poor sublingual bioavailability) to deter intravenous misuse. Approved for opioid use disorder and chronic pain (transdermal Butrans). The kappa-opioid antagonism is being investigated for treatment-resistant depression. Used as the canonical mu-opioid partial agonist in addiction medicine.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-350Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Tapentadol

Plain-language summaryIntrigue 56 / 100

Tapentadol, sold as Nucynta, is a more deliberate redesign of the dual opioid plus norepinephrine mechanism that tramadol got accidentally. It binds the mu-opioid receptor directly with moderate affinity (no reliance on a CYP2D6-generated metabolite) and inhibits norepinephrine reuptake without touching serotonin, eliminating the serotonin syndrome risk. The opioid effect plus norepinephrine pain modulation produces clinical analgesia comparable to oxycodone with less constipation and nausea in many patients. It remains a controlled substance with full opioid dependence potential. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

52/100

A refined dual MOR/NRI analgesic with solid clinical record but limited frontier research appeal

Here’s the thing about tapentadol: it’s a well-engineered analgesic that solved a real problem and then mostly became a clinical drug, not a research frontier. The dual MOR agonism plus norepinephrine reuptake inhibition story is genuinely elegant. By combining complementary analgesic pathways, Grunenthal managed to produce equianalgesic potency at lower mu-receptor occupancy, which translates into measurable reductions in opioid-typical side effects like constipation and respiratory depression. Thats not nothing. The absence of meaningful SERT activity is a real advantage over tramadol, removing the serotonin syndrome risk that makes tramadol awkward in mixed-therapy contexts.

But tapentadol got FDA approval in 2008. That’s seventeen years of clinical use, well-replicated trial data in chronic low back pain, diabetic peripheral neuropathy, and postoperative settings, and a mechanism thats now thoroughly understood and taught in pharmacology courses. The dual MOR/NRI class doesnt have many active open questions at the bench level. The mechanism is characterized, the PK is clean (glucuronidation, no active metabolites, four-hour half-life), and the clinical picture is settled. What remains interesting is fairly narrow: using it as a reference compound to dissect the relative contributions of mu-opioid versus adrenergic mechanisms to analgesia, or in comparative pharmacology work where you want a clean MOR/NRI with no serotonin confounds.

Evidence quality and translational signal are genuinely strong here. Multiple phase 3 RCTs, regulatory approval across multiple jurisdictions, replicated across pain phenotypes. We’re not questioning whether it works. What we’re questioning is whether a bench investigator in 2026 finds tapentadol a compelling object of inquiry versus a well-characterized tool they might reach for when designing assays, not when choosing a research program.

The Schedule II status is a real friction point for research access, and it places the compound in a category where the burden of novelty is higher to justify the logistics. Tapentadol doesnt clear that bar. It’s the cleanest representative of a class that’s now mature, and the remaining questions in opioid pharmacology are moving toward biased agonism, arrestin pathway modulation, and functional selectivity work where newer probes are doing the heavy lifting. Tapentadol can serve as a solid comparator or reference standard in such work, but it’s unlikely to be the compound that moves the needle in 2026.

We’d score this for what it is: a well-understood approved drug with good evidence and a genuinely interesting mechanism that has largely been characterized. Worth knowing; not a priority research target.

Novelty

28

Mechanism promise

50

In-category differentiation

45

Evidence quality

72

Translational signal

73

Research bench value

55

Rationale Tapentadol’s Schedule II cap of 65 doesn’t bind because the raw score lands around 52 on its own merits: the dual MOR/NRI mechanism is genuinely differentiated from tramadol but is now a mature, well-characterized pharmacology with limited frontier novelty. Strong evidence and translational scores pull it up; low novelty and moderate differentiation keep it in established-mature territory.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Mu-opioid agonist + norepinephrine reuptake inhibitor

A mu-opioid agonist with norepinephrine reuptake inhibition; an analgesic with reduced opioid side effects through the dual mechanism.

Abstract

Tapentadol (3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol; CAS 175591-23-8; molecular formula C14H23NO; molecular weight 221.34) is a mu-opioid agonist with norepinephrine reuptake inhibition developed at Grunenthal and approved by the FDA in 2008 (Nucynta). The compound is a moderate-affinity mu-opioid agonist (Ki approximately 0.16 microM, intermediate between morphine and tramadol) with concurrent NET inhibition (Ki approximately 0.5 microM); distinct from tramadol by absence of meaningful SERT activity, eliminating the serotonin syndrome risk. The dual MOR/NRI mechanism produces strong analgesia with reduced opioid-mediated side effects (constipation, nausea, respiratory depression) at equianalgesic doses, an opioid-sparing effect supported by clinical trials. Plasma half-life is approximately 4 hours; metabolism is via glucuronidation (no active metabolites). Schedule II in the US (higher than tramadol). Used as a reference dual MOR/NRI analgesic in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-349Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Zolpidem

Plain-language summaryIntrigue 58 / 100

Zolpidem, sold as Ambien, is the most prescribed prescription sleep aid in the United States. It belongs to the Z-drug class, which were designed to act selectively at the alpha-1 subtype of GABA-A receptors that drives sedation, theoretically avoiding the anxiolytic and muscle-relaxant effects (and the dependence) of benzodiazepines. In practice the selectivity is partial and dependence does develop with chronic use. Zolpidem is also notorious for next-day amnesia and unusual nocturnal behaviors (sleep-driving, sleep-eating) that prompted FDA dose reductions, particularly for women, who clear the drug more slowly. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

43/100

Canonical Z-drug hypnotic; alpha-1 selectivity is a useful pharmacological probe but the compound is pharmacologically mature

Look, zolpidem is about as well-understood as a CNS compound gets. FDA approval in 1992 as Ambien, massive post-marketing surveillance, black-box warnings from complex sleep behaviors, CYP3A4 metabolism characterized to the last detail. The alpha-1 selectivity story was genuinely interesting when it emerged from Synthelabo’s program because it separated the sedative/hypnotic effect from the anxiolytic, muscle-relaxant, and anticonvulsant effects that made benzodiazepines problematic. That’s a real pharmacological achievement. The question is whether it’s an interesting research achievement in 2025, and the honest answer is mostly no.

The mechanism is clean and the subtype selectivity (Ki approximately 20 nM at alpha-1, substantially lower affinity at alpha-2, alpha-3, and alpha-5) gives zolpidem genuine value as a pharmacological tool for dissecting GABA-A subunit contributions to behavior. We think that’s the most defensible reason to keep this in a research library. If you’re running a program trying to understand alpha-1 vs. alpha-5 contributions to amnestic effects, or mapping the behavioral correlates of subunit-selective PAMs, zolpidem is a reasonable reference. That’s the bench value argument, and it’s modest but real.

What we don’t like: the field has moved. Dual orexin receptor antagonists like suvorexant and lemborexant represent a fundamentally different mechanistic approach to sleep pharmacology, and they’ve largely displaced Z-drugs in clinical interest. The questions researchers are now asking about sleep architecture, glymphatic clearance, and circadian biology don’t center on GABA-A modulation the way they did in the 1990s and early 2000s. Zolpidem answers questions that are mostly already answered.

The evidence base is enormous but it reads as a closed book rather than an open one. Multiple decade-long cohort studies, pharmacokinetic profiling across populations, drug interaction data, the FDA black-box revision in 2013. All of this tells a complete story. There’s no contested mechanism to probe, no unexpected signal to chase, no second-indication hypothesis with real momentum. The complex sleep behavior literature is genuinely interesting from a neuroscience standpoint, but it’s more cautionary than exploratory at this point.

Differentiation is the real ceiling here. As a hypnotic, its once-distinctive alpha-1 story is now table stakes for the class, and its clinical profile carries baggage the newer orexin antagonists don’t. As a research tool, there are cleaner subunit-selective compounds that serve the same probe function with less pharmacological noise. Zolpidem sits in the useful-but-not-exciting tier: worth having as a reference, not worth building a program around.

Novelty

22

Mechanism promise

35

In-category differentiation

32

Evidence quality

72

Translational signal

65

Research bench value

50

Rationale Zolpidem is a 1992 FDA-approved Schedule IV compound with fully characterized mechanism and enormous clinical literature, but novelty and differentiation are low given newer orexin antagonist hypnotics have supplanted it clinically; bench value as an alpha-1 GABA-A subtype-selective probe saves it from scoring lower.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Imidazopyridine selective alpha-1 GABA-A agonist (Z-drug)

An imidazopyridine Z-drug hypnotic; a selective alpha-1-containing GABA-A receptor positive modulator with reduced anxiolytic and muscle-relaxant effects.

Abstract

Zolpidem (N,N,6-trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide; CAS 82626-48-0; molecular formula C19H21N3O; molecular weight 307.39) is an imidazopyridine Z-drug hypnotic developed at Synthelabo and approved by the FDA in 1992 (Ambien). The compound is a positive allosteric modulator of GABA-A receptors at the benzodiazepine site, but with selectivity for alpha-1-containing receptor subtypes (Ki approximately 20 nM) over alpha-2, alpha-3, and alpha-5 (lower affinity). The alpha-1 selectivity produces sedation/hypnosis without the anxiolytic, muscle-relaxant, and anticonvulsant effects of benzodiazepines (which engage all four alpha subtypes). Plasma half-life is approximately 2.5 hours; metabolism is via CYP3A4. Approved for short-term treatment of insomnia. The compound has well-documented complex sleep behaviors (sleepwalking, sleep-driving, sleep-eating) and amnestic effects, with notable case reports of bizarre nighttime behavior leading to FDA black-box warnings. Used as the canonical Z-drug in sleep pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-347Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Tramadol

Plain-language summaryIntrigue 56 / 100

Tramadol, sold as Ultram, is an atypical opioid analgesic that combines weak direct mu-opioid receptor binding with serotonin and norepinephrine reuptake inhibition (the SNRI mechanism shared with antidepressants). The opioid effect comes mostly from a metabolite called M1, generated by the CYP2D6 liver enzyme, which means CYP2D6 ultra-rapid metabolizers (about 7 percent of Caucasians, higher in some other populations) get dramatic opioid effects from standard doses. The dual mechanism creates two distinct hazards: opioid dependence and serotonin syndrome when combined with SSRIs or other serotonergic drugs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

44/100

Mature atypical opioid fully characterized; canonical reference compound with no active frontier research angle

Look, tramadol is about as thoroughly characterized as a drug gets. Developed at Grunenthal in the 1970s, FDA approved in 1995 as Ultram, and then rescheduled to Schedule IV in 2014 after accumulating abuse data. The dual mechanism (weak mu-opioid receptor agonism plus serotonin-norepinephrine reuptake inhibition) was genuinely interesting when first described. Thats not 2026.

The pharmacology is textbook at this point. The parent compound has modest mu-opioid affinity (Ki around 2 microM), and the real opioid activity comes from CYP2D6-mediated conversion to O-desmethyltramadol (M1), which sits roughly 200-fold higher in receptor affinity. The SNRI component contributes to the analgesic profile but also creates the serotonin syndrome risk that makes combination use genuinely dangerous. SERT Ki around 1 microM, NET Ki around 0.4 microM. None of this is contested. None of it is novel. It’s the kind of mechanism that gets a single textbook paragraph and stays there.

Where tramadol does earn its keep is as a reference compound for specific mechanistic work. CYP2D6 pharmacogenomics researchers use it as a clean model for prodrug activation studies, given how neatly M1 formation maps to metabolizer phenotype. Serotonin syndrome risk modeling uses tramadol as a canonical dual-mechanism case when probing drug-drug interaction space. That’s real value, and we credit it. But it’s narrow, and those aren’t frontier questions.

The evidence base is actually quite solid relative to a lot of what’s in the library. Decades of clinical PK/PD data, well-replicated across diverse populations, good pharmacogenomic characterization of poor versus ultrarapid CYP2D6 metabolizer outcomes. Evidence quality isn’t the limiting factor here. The issue is that all that evidence has already answered the questions it was built to answer.

We don’t see an emerging research angle that would push tramadol back onto a serious investigator’s priority list. It’s not being repurposed for a novel indication with real momentum. It’s not a sharper probe than alternatives for the opioid questions that actually matter right now, things like OPRM1 allosterism, biased agonism at the mu receptor, or opioid-sparing combination mechanisms. The Schedule IV status adds real regulatory friction without any corresponding research upside. If you’re building a program around pain pharmacology, there are cleaner tools for every question tramadol can address. It sits in the library primarily as a reference standard for dual-mechanism analgesic work, and that’s about the ceiling.

Novelty

20

Mechanism promise

30

In-category differentiation

40

Evidence quality

75

Translational signal

70

Research bench value

45

Rationale Evidence quality and translational signal are high (approved drug, decades of replicated clinical PK/PD data), but novelty and mechanism interest are low: 1970s compound, completely characterized pharmacology, no emerging repurposing signal. Bench value is modest but real as a CYP2D6 prodrug model and serotonin syndrome reference case, insufficient to substantially elevate the overall.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Atypical opioid (mu-opioid + SNRI)

A weak mu-opioid agonist with serotonin-norepinephrine reuptake inhibition; an atypical analgesic with abuse and serotonin syndrome risk.

Abstract

Tramadol ((1R,2R)-rel-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol; CAS 27203-92-5; molecular formula C16H25NO2; molecular weight 263.38) is an atypical opioid analgesic developed at Grunenthal in the 1970s and approved by the FDA in 1995 (Ultram). The compound is a weak mu-opioid receptor agonist (Ki approximately 2 microM, low affinity); the active metabolite O-desmethyltramadol (M1, formed via CYP2D6) has approximately 200-fold higher mu-opioid affinity. Distinct from pure opioids by additional serotonin and norepinephrine reuptake inhibition (SERT Ki approximately 1 microM, NET Ki approximately 0.4 microM), contributing to the analgesic profile and to serotonin syndrome risk when combined with other serotonergic drugs. Plasma half-life is approximately 6 hours; metabolism is via CYP2D6 (M1 production) and CYP3A4. Schedule IV in the US since 2014. The combined opioid and SNRI activity produces seizures (rare at therapeutic doses, more common in overdose), serotonin syndrome (with concurrent serotonergic drugs), and abuse potential intermediate between non-opioid analgesics and full opioids. Used as the canonical atypical opioid in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-348Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Sodium Oxybate (GHB)

Our opinion on this compoundFederally scheduled

57/100

Canonical GHB receptor probe and approved narcolepsy drug with serious regulatory burden and limited novelty

Look, sodium oxybate is a genuinely weird compound to score because it lives in two regulatory worlds simultaneously. As Xyrem its Schedule III; as free-base GHB its Schedule I. That dual status isnt just an administrative footnote for a bench scientist. It shapes everything about sourcing, handling, institutional approval, and the realistic scope of an investigator’s research program. We’re not penalizing it for being controlled, but we’re not pretending that friction doesn’t exist either.

The pharmacology itself is interesting in a way that doesn’t fully show up until you dig into the receptor biology. GHB has two binding targets: a high-affinity, low-capacity GHB-specific receptor (Kd around 50 nM) and low-affinity GABA-B (Ki around 5 mM). At clinically relevant doses, GABA-B dominates the functional output, but the GHB receptor is a genuinely understudied piece of neuropharmacology. It’s not GABA-B, its not an opioid receptor, its not something well-mapped by standard psychopharmacology toolsets. If you’re trying to untangle GHB receptor-specific signaling from GABA-B contributions, sodium oxybate is essentially the only game in town. That gives it real probe value that pure mechanism scores alone dont fully capture.

The evidence base is solid by research-library standards. Xyrem went through multiple Phase 3 RCTs for narcolepsy and has a decade-plus of post-approval pharmacovigilance. The slow-wave sleep consolidation effect is one of the cleaner mechanistic demonstrations in clinical sleep pharmacology. European data on alcohol dependence is messier and more contested, but there’s a real multi-lab literature there, not just a single consortium claiming results nobody else can replicate.

What drags the score down is novelty, and honestly that’s appropriate. This is not a compound where a serious bench scientist is going to find white space easily. The narcolepsy mechanism is well-characterized. The GABA-B angle has baclofen as a cleaner alternative for most purposes. The alcohol dependence angle is still alive but crowded with competing pharmacological approaches. If your research program requires specifically interrogating GHB receptor biology, sodium oxybate is indispensable. If your program only tangentially touches it, the regulatory cost isnt worth it when better-characterized GABA-B probes are on the shelf.

We think this one sits around the 57 range: too mature and too well-understood to score higher on novelty, but too pharmacologically unique and too clinically validated to score lower. The GHB receptor remains one of the weirder and less-answered questions in CNS pharmacology. That keeps it above pure workhorse territory.

Novelty

30

Mechanism promise

52

In-category differentiation

60

Evidence quality

72

Translational signal

74

Research bench value

65

Rationale Calculated overall of 57 sits below both the Schedule III cap (75) and Schedule I cap (65), so no cap binds; the score reflects a mature approved drug with genuine bench utility as the only pharmacological handle on GHB receptor biology, but low novelty and a dual scheduling status that creates significant access friction for investigators.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GHB receptor agonist / GABA-B partial agonist

Sodium gamma-hydroxybutyrate; an endogenous neurotransmitter and prescription medication for narcolepsy and (controversially) alcoholism.

Abstract

Sodium oxybate (sodium 4-hydroxybutanoate, GHB; CAS 502-85-2; molecular formula C4H7NaO3; molecular weight 126.09) is the sodium salt of gamma-hydroxybutyrate, an endogenous short-chain fatty acid neurotransmitter and metabolite of GABA. The compound binds two distinct receptors: high-affinity GHB receptors (Kd approximately 50 nM, low capacity) and low-affinity GABA-B receptors (Ki approximately 5 mM, high capacity); pharmacologically meaningful effects at clinical doses are predominantly GABA-B-mediated. Approved indications: narcolepsy with cataplexy and excessive daytime sleepiness; clinical effect involves consolidation of slow-wave sleep. Used in some European countries (notably Italy, France) for alcohol withdrawal and dependence treatment. Schedule III when prescribed as Xyrem; Schedule I as illicit GHB. The narrow therapeutic index makes overdose easy and dangerous; recreational misuse with predatory drug-facilitated assault has been a significant public health issue. Plasma half-life is approximately 0.5 to 1 hour. Used as the canonical GHB receptor and GABA-B partial agonist in academic neuroscience.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-346Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Etomidate

Plain-language summaryIntrigue 54 / 100

Etomidate is an intravenous induction anesthetic used when cardiovascular stability matters most, such as in trauma patients with low blood pressure or those with significant heart disease. It enhances GABA-A signaling at a different site than propofol and produces minimal blood pressure or heart rate changes. The major liability is adrenocortical suppression: etomidate inhibits the 11-beta-hydroxylase enzyme that synthesizes cortisol, and even a single induction dose meaningfully suppresses cortisol production for up to 24 hours. This has limited its use in septic patients, where adrenal suppression is harmful. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

48/100

Mature IV anesthetic; cardiovascular-stable reference probe with CYP11B1 inhibition as its most interesting research legacy

Look, etomidate is one of those compounds that earns its place in a research library on the strength of what it does, not how exciting it is to talk about. Approved by the FDA as Amidate back in 1972, this imidazole IV anesthetic has been a clinical fixture for over five decades, and the research community has had ample time to pick it apart. Thats actually the problem from a research-novelty standpoint: there’s not much left to discover about the parent compound.

The mechanism is worth understanding even if it isnt surprising. Etomidate acts as a positive allosteric modulator at GABA-A receptors with preferential binding to the beta-2 and beta-3 subunits. That subunit selectivity differentiates it from benzodiazepines, which prefer alpha subunit interfaces, and it’s genuinely useful as a pharmacological probe for dissecting GABA-A subtype contributions to sedation and anesthesia. Work from the Forman group at MGH and others has used etomidate-based analogues to map out the transmembrane binding pocket in real detail. As a molecular tool for that specific question, it holds up.

The more compelling research angle, honestly, is the adrenocortical suppression. Etomidate inhibits CYP11B1 (11-beta-hydroxylase), the terminal enzyme in cortisol biosynthesis, with enough potency that a single induction dose suppresses cortisol output for four to six hours. In critically ill ICU patients, this became a serious clinical concern after the Ledingham and Watt findings in the early 1980s, which drove entire analog programs: methoxycarbonyl etomidate, cyclopropyl-MOC-etomidate, and the carboetomidate series are all direct descendants of that liability. Etomidate itself is now the benchmark comparator for studying selective CYP11B1 inhibition, which carries its own therapeutic interest for adrenal excess conditions like Cushing’s syndrome.

What we like: the cardiovascular stability is real and multiply confirmed across decades of clinical use, the beta-subunit-selective GABA-A story has genuine probe value for receptor biology programs, and the CYP11B1 inhibition it revealed spawned research that is arguably more interesting than the compound itself. What we dont like: the parent compound is entirely mature. There is no frontier angle remaining on etomidate proper, and the adrenocortical liability has pushed serious investigators toward next-generation analogs rather than back to the original scaffold.

If your program involves GABA-A subunit pharmacology, CYP11B1 inhibitor screening, or steroidogenesis inhibition analog design, etomidate is a solid reference standard and a logical starting point for comparative work. As a primary research target in 2026, it’s not where you’d put your time. The interesting work is happening in what etomidate spawned, not in the original compound itself.

Novelty

22

Mechanism promise

33

In-category differentiation

48

Evidence quality

72

Translational signal

75

Research bench value

58

Rationale Approved 1972 with a thoroughly characterized mechanism, etomidate scores on evidence and translational signal but loses heavily on novelty and mechanism freshness; its primary research value today is as a reference tool for GABA-A subunit pharmacology and CYP11B1 inhibitor development, not as a primary investigation target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GABA-A receptor positive allosteric modulator (intravenous anesthetic)

An imidazole intravenous induction anesthetic; cardiovascular stable but causes adrenocortical suppression.

Abstract

Etomidate ((R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester; CAS 33125-97-2; molecular formula C14H16N2O2; molecular weight 244.29) is an imidazole intravenous induction anesthetic developed at Janssen and approved by the FDA in 1972 (Amidate). The compound is a GABA-A receptor positive allosteric modulator with a binding site at the beta-2 and beta-3 subunits that produces preferential activity at extrasynaptic and synaptic GABA-A receptors. Distinct among IV anesthetics by minimal cardiovascular effects (preserved blood pressure and heart rate), making it preferred for patients with hemodynamic instability. The principal limitation is dose-dependent inhibition of 11-beta-hydroxylase (CYP11B1), the final enzyme in cortisol biosynthesis; even a single induction dose suppresses cortisol for 4 to 6 hours, with potential clinical consequence in critically ill patients. Plasma half-life is approximately 2 to 5 hours. Used as a reference IV anesthetic with cardiovascular stability and adrenocortical suppression.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-345Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Dexmedetomidine

Plain-language summaryIntrigue 68 / 100

Dexmedetomidine, sold as Precedex, is an intravenous sedative that works through alpha-2A adrenergic receptors in the brainstem rather than through the GABA system used by virtually every other sedative. The unusual mechanism has a clinically remarkable consequence: it produces sedation that resembles natural sleep, from which patients can be awakened to follow commands, without depressing respiration. It is heavily used in intensive care units for ventilated patients and procedural sedation. The main side effects are bradycardia and hypotension from systemic alpha-2 activation. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

55/100

Best-in-class alpha-2A probe with deep clinical evidence but low novelty and a narrow research niche

Look, dexmedetomidine is genuinely useful, and we want to be precise about why that doesnt translate into a high score here. The compound has been approved since 1999 under Precedex, the mechanism is textbook-level understood, and the clinical story is already told. ICU sedation, procedural sedation, arousable sleep-mimicking pharmacology via locus coeruleus alpha-2A activation. None of that is surprising to anyone who’s opened an anesthesia pharmacology chapter in the last two decades.

What dexmedetomidine does have going for it is probe selectivity. The 1620-fold preference for alpha-2 over alpha-1 receptors is substantially cleaner than clonidine, which sits closer to 200-fold. If you’re running experiments that require isolating alpha-2A-mediated effects without alpha-1 contamination, dexmedetomidine is the tool. Thats the bench value case, and it’s real. Its why the compound ends up in papers on adrenergic receptor subtype biology, sympatholytic pharmacology, delirium prevention mechanisms, and the neurochemistry of natural sleep versus drug-induced sedation. As a pharmacological probe, it earns its place on the shelf.

But the research conversation around dexmedetomidine isnt particularly live or frontier-facing. The mechanism of action at the locus coeruleus and spinal cord is fully characterized. The clinical evidence base is robust by any measure, which is exactly the problem from a novelty perspective. When a drug has undergone decades of multicenter trials and sits in anesthesiology formularies worldwide, the interesting questions have mostly been answered. What’s left is refinement: pediatric dosing optimization, opioid-sparing protocols, delirium incidence in specific ICU subpopulations. Legitimate work, but not the kind that demands a dedicated research program for a bench scientist who isn’t already in that clinical orbit.

We think the differentiation score is the honest bright spot. Among alpha-2 agonists available as research tools, dexmedetomidine is clearly the reference standard. Clonidine is cheaper and more accessible but pharmacologically messier. Guanfacine has the alpha-2A selectivity story but in a different pharmacokinetic and CNS-distribution context. For receptor-level mechanistic work, dex is the right choice. That matters for labs doing adrenergic subtype work or investigating the molecular basis of norepinephrine-mediated sedation.

Honestly, the 55 reflects a compound that is precisely as useful as it looks and not one point more. It’s not overlooked, not underrated, not sitting on a hidden research signal. The literature is mature, the mechanism is settled, and the novelty clock stopped running a long time ago. Serious researchers in alpha-2A biology or ICU neuroscience will already know it. Everyone else can deprioritize it without missing anything.

Novelty

20

Mechanism promise

40

In-category differentiation

65

Evidence quality

78

Translational signal

72

Research bench value

75

Rationale Dexmedetomidine scores high on differentiation and bench value because its 1620:1 alpha-2:alpha-1 selectivity makes it the canonical tool for isolating alpha-2A-specific effects, but the compound is 25 years old, the mechanism is fully characterized, and the translational story is already written by the FDA approval. Score reflects a useful but unexciting research probe, not a frontier target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective alpha-2A adrenergic agonist (anesthetic)

A potent selective alpha-2A adrenergic agonist; an intravenous sedative producing arousable sedation without respiratory depression.

Abstract

Dexmedetomidine ((S)-4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole; CAS 113775-47-6; molecular formula C13H16N2; molecular weight 200.28) is a highly selective alpha-2A adrenergic agonist developed at Farmos and approved by the FDA in 1999 (Precedex). The compound is the active S-enantiomer of medetomidine (used in veterinary anesthesia). Alpha-2A selectivity over alpha-2B and alpha-2C is approximately 8-fold; selectivity over alpha-1 is approximately 1620-fold, much higher than clonidine. The clinical profile is unique: the alpha-2A activation in the locus coeruleus produces sedation that mimics natural sleep architecture, with patients arousable on stimulation; respiratory drive is preserved. Approved indications: ICU sedation, procedural sedation, conscious sedation. Plasma half-life is approximately 2 hours; metabolism is hepatic. Used as the canonical highly selective alpha-2A agonist in anesthesia research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-343Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 52 53 54 55 56 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.